@article{NaithaniKlostermeyerLangeetal.1971,
  author    = {Naithani, V. K and Klostermeyer, Henning and Lange, H. R. and [u.a.], and Berndt, Heinz and [u.a.],},
  title     = {Preparation of peptide derivatives for porcine proinsulin-synthesis},
  series = {Biological Chemistry},
  volume    = {352},
  journal   = {Biological Chemistry},
  number    = {1},
  publisher = {De Gruyter},
  issn      = {1437-4315},
  doi       = {10.1515/bchm2.1971.352.1.1},
  pages     = {2 -- 3},
  year      = {1971},
  language  = {en}
}
@article{SchwertnerBerndtGielenetal.1975,
  author    = {Schwertner, Eberhard and Berndt, Heinz and Gielen, Hans-G{\"u}nter and Zahn, Helmut},
  title     = {Peptide 96 : Synthese einiger [2-(p-Biphenylyl)isopropyloxycarbonyl]-Aminos{\"a}urederivate},
  series = {Justus Liebigs Annalen der Chemie},
  volume    = {75},
  journal   = {Justus Liebigs Annalen der Chemie},
  number    = {3},
  publisher = {Wiley-VCH},
  address   = {Weinheim},
  issn      = {1099-0690},
  doi       = {10.1002/jlac.197519750318},
  pages     = {581 -- 585},
  year      = {1975},
  abstract  = {Die Darstellung der N-[2-(p-Biphenylyl)isopropyloxycarbonyl]-Derivate (Bpoc-Derivate) des Cysteins unter Verwendung der Thiolschutzgruppen Tetrahydropyranyl (Thp) f{\"u}r 1, Diphenylmethyl (Dpm) f{\"u}r 2, Trityl (Trt) f{\"u}r 3 und S-tert.-Butyl (SBut) f{\"u}r 4 sowie die Synthese von aktivierten Estern der Bpoc-Derivate des Glycins (5), Isoleucins (6) und Prolins (7) werden beschrieben. An einem Beispiel wird die M{\"o}glichkeit aufgezeigt, die Bpoc-Gruppe {\"u}ber das Bpoc-Azid nachtr{\"a}glich in den Peptidverband einzuf{\"u}hren.},
  language  = {de}
}
@article{WolfBerndtBrandenburg1979,
  author    = {Wolf, G{\"u}nter and Berndt, Heinz and Brandenburg, Dietrich},
  title     = {Synthese der [LysA13] Rinderinsulin-A-Kette in der Form [Lys(Tfa)A13]A(SO3H)4 und NαA1-Msc-[LysA13]A(SO3H)4 unter Verwendung des S-tert-Butylmercapto-Restes als Thiolschutzgruppe},
  series = {Hoppe-Seyler's Zeitschrift f{\"u}r physiologische Chemie},
  volume    = {360},
  journal   = {Hoppe-Seyler's Zeitschrift f{\"u}r physiologische Chemie},
  number    = {2},
  issn      = {1437-4315},
  doi       = {10.1515/bchm2.1979.360.2.1569},
  pages     = {1569 -- 1578},
  year      = {1979},
  language  = {de}
}
@incollection{TippkoetterMoehringRothetal.2019,
  author    = {Tippk{\"o}tter, Nils and M{\"o}hring, Sophie and Roth, Jasmine and Wulfhorst, Helene},
  title     = {Logistics of lignocellulosic feedstocks: preprocessing as a preferable option},
  series = {Biorefineries},
  booktitle = {Biorefineries},
  publisher = {Springer},
  address   = {Cham},
  isbn      = {978-3-319-97117-9},
  doi       = {10.1007/10_2017_58},
  pages     = {43 -- 68},
  year      = {2019},
  abstract  = {In comparison to crude oil, biorefinery raw materials are challenging in concerns of transport and storage. The plant raw materials are more voluminous, so that shredding and compacting usually are necessary before transport. These mechanical processes can have a negative influence on the subsequent biotechnological processing and shelf life of the raw materials. Various approaches and their effects on renewable raw materials are shown. In addition, aspects of decentralized pretreatment steps are discussed. Another important aspect of pretreatment is the varying composition of the raw materials depending on the growth conditions. This problem can be solved with advanced on-site spectrometric analysis of the material.},
  language  = {en}
}
@article{MatoniBerndt1980,
  author    = {Matoni, Georg and Berndt, Heinz},
  title     = {Thermal synthesis of the optical pure pentapeptide derivative Z-(L)-Ala-(L)-Phe-Gly-(L)-Phe-Gly-OMe},
  series = {Tetrahedron letters},
  volume    = {21},
  journal   = {Tetrahedron letters},
  number    = {1},
  issn      = {0040-4039},
  doi       = {10.1016/S0040-4039(00)93618-9},
  pages     = {37 -- 40},
  year      = {1980},
  language  = {en}
}
@article{ScheerKapelyukhRodeetal.2015,
  author    = {Scheer, Nico and Kapelyukh, Yury and Rode, Anja and Oswald, Stefan and Busch, Diana and Mclaughlin, Lesley A. and Lin, De and Henderson, Colin J. and Wolf, C. Roland},
  title     = {Defining Human Pathways of Drug Metabolism In Vivo through the Development of a Multiple Humanized Mouse Model},
  series = {Drug Metabolism and Disposition},
  volume    = {43},
  journal   = {Drug Metabolism and Disposition},
  number    = {11},
  publisher = {ASPET},
  address   = {Bethesda},
  issn      = {1521-009x},
  doi       = {10.1124/dmd.115.065656},
  pages     = {1679 -- 1690},
  year      = {2015},
  language  = {en}
}
@inproceedings{BerndtKalbeKuropkaetal.1990,
  author    = {Berndt, Heinz and Kalbe, Jochen and Kuropka, Rolf and Meyer-Stork, L. Sebastian and H{\"o}cker, Hartwig},
  title     = {Progress and limitations of the DNA analysis in fine animal fiber identification},
  series = {Proceedings of the 2nd International Symposium on Specialty Animal Fibers : Aachen, October 19 - 20, 1989. - (Schriftenreihe des Deutschen Wollforschungsinstituts an der Technischen Hochschule Aachen e. V. ; 106)},
  booktitle = {Proceedings of the 2nd International Symposium on Specialty Animal Fibers : Aachen, October 19 - 20, 1989. - (Schriftenreihe des Deutschen Wollforschungsinstituts an der Technischen Hochschule Aachen e. V. ; 106)},
  editor    = {K{\"o}rner, Andrea},
  publisher = {Dt. Wollforschungsinst.},
  address   = {Aachen},
  pages     = {259 -- 265},
  year      = {1990},
  language  = {en}
}
@article{ZhangHeimbachScheeretal.2016,
  author    = {Zhang, Jin and Heimbach, Tycho and Scheer, Nico and Barve, Avantika and Li, Wenkui and Lin, Wen and He, Handan},
  title     = {Clinical Exposure Boost Predictions by Integrating Cytochrome P450 3A4-Humanized Mouse Studies With PBPK Modeling},
  series = {Journal of Pharmaceutical Sciences},
  volume    = {Volume 105},
  journal   = {Journal of Pharmaceutical Sciences},
  number    = {Issue 4},
  publisher = {Elsevier},
  address   = {Amsterdam},
  issn      = {0022-3549},
  doi       = {doi.org/10.1016/j.xphs.2016.01.021},
  pages     = {1398 -- 1404},
  year      = {2016},
  abstract  = {NVS123 is a poorly water-soluble protease 56 inhibitor in clinical development. Data from in vitro hepatocyte studies suggested that NVS123 is mainly metabolized by CYP3A4. As a consequence of limited solubility, NVS123 therapeutic plasma exposures could not be achieved even with high doses and optimized formulations. One approach to overcome NVS123 developability issues was to increase plasma exposure by coadministrating it with an inhibitor of CYP3A4 such as ritonavir. A clinical boost effect was predicted by using physiologically based pharmacokinetic (PBPK) modeling. However, initial boost predictions lacked sufficient confidence because a key parameter, fraction of drug metabolized by CYP3A4 (ƒₘCYP3A4), could not be estimated with accuracy on account of disconnects between in vitro and in vivo preclinical data. To accurately estimate ƒₘCYP3A4 in human, an in vivo boost effect study was conducted using CYP3A4-humanized mouse model which showed a 33- to 56-fold exposure boost effect. Using a top-down approach, human ƒₘCYP3A4 for NVS123 was estimated to be very high and included in the human PBPK modeling to support subsequent clinical study design. The combined use of the in vivo boost study in CYP3A4-humanized mouse model mice along with PBPK modeling accurately predicted the clinical outcome and identified a significant NVS123 exposure boost (∼42-fold increase) with ritonavir.},
  language  = {en}
}
@article{ScheerBalimaneHaywardetal.2012,
  author    = {Scheer, Nico and Balimane, Praveen and Hayward, Michael D. and Buechel, Sandra and Kauselmann, Gunther and Wolf, C. Roland},
  title     = {Generation and Characterization of a Novel Multidrug Resistance Protein 2 Humanized Mouse Line},
  series = {Drug Metabolism and Disposition},
  volume    = {40},
  journal   = {Drug Metabolism and Disposition},
  number    = {11},
  publisher = {ASPET},
  address   = {Bethesda, Md.},
  issn      = {1521-0111},
  doi       = {10.1124/dmd.112.047605},
  pages     = {2212 -- 2218},
  year      = {2012},
  abstract  = {The multidrug resistance protein (MRP) 2 is predominantly expressed in liver, intestine, and kidney, where it plays an important role in the excretion of a range of drugs and their metabolites or endogenous compounds into bile, feces, and urine. Mrp knockout [Mrp2(-/-)] mice have been used recently to study the role of MRP2 in drug disposition. Here, we describe the first generation and initial characterization of a mouse line humanized for MRP2 (huMRP2), which is nulled for the mouse Mrp2 gene and expresses the human transporter in the organs and cell types where MRP2 is normally expressed. Analysis of the mRNA expression for selected cytochrome P450 and transporter genes revealed no major changes in huMRP2 mice compared with wild-type controls. We show that human MRP2 is able to compensate functionally for the loss of the mouse transporter as demonstrated by comparable bilirubin levels in the humanized mice and wild-type controls, in contrast to the hyperbilirubinemia phenotype that is observed in MRP2(-/-) mice. The huMRP2 mouse provides a model to study the role of the human transporter in drug disposition and in assessing the in vivo consequences of inhibiting this transporter by compounds interacting with human MRP2.},
  language  = {en}
}
@article{AbulnagaPinkenburgSchiffelsetal.2013,
  author    = {Abulnaga, El-Hussiny and Pinkenburg, Olaf and Schiffels, Johannes and E-Refai, Ahmed and Buckel, Wolfgang and Selmer, Thorsten},
  title     = {Effect of an Oxygen-Tolerant Bifurcating Butyryl Coenzyme A Dehydrogenase/Electron-Transferring Flavoprotein Complex from Clostridium difficile on Butyrate Production in Escherichia coli},
  series = {Journal of bacteriology},
  volume    = {195},
  journal   = {Journal of bacteriology},
  number    = {16},
  issn      = {1098-5530 [E-Journal]},
  pages     = {3704 -- 3713},
  year      = {2013},
  language  = {en}
}